A carregar...
Publicação
GLP-1 receptor agonists for obesity: eligibility across 99 countries
| Nome: | Descrição: | Tamanho: | Formato: | |
|---|---|---|---|---|
| 33.27 KB | Adobe PDF | |||
| 178.49 KB | Adobe PDF |
Orientador(es)
Resumo(s)
We analysed pooled, individual participant data from nationally representative, cross-sectional household health surveys conducted in 99 countries between 2008 and 2021 (appendix pp 2–67). Our sample comprised non-pregnant individuals aged 25–64 years with an available diabetes biomarker, blood pressure measurement, and BMI measurement, as well as complete data on hypertension and diabetes diagnoses (appendix pp 69–75). Eligibility for GLP-1 receptor agonists was determined by applying the inclusion criteria from key randomised clinical trials.3,4 Individuals were defined as eligible for GLP-1 receptor agonists for weight management if they had a BMI of 30 kg/m2 or more or a BMI of 27 kg/m2 or more with hypertension or diabetes, or both—two common weight-related comorbidities. Hypertension was defined based on measured blood pressure and diabetes was defined based on glycaemic markers (HbA1c and plasma glucose). We did not consider other obesity-related comorbidities, such as obstructive sleep apnoea or cardiovascular disease, because data were not consistently available across surveys. For countries in the south, east, and southeast Asian region, we adjusted the eligibility to a BMI of 28 kg/m2 or more or a BMI of 24 kg/m2 or more with hypertension or diabetes, or both, in line with regionally based clinical trials.6 All statistical analyses included sampling weights that we rescaled in proportion to the countries’ population sizes. This study was deemed exempt from regulation by the institutional review board at the University of Michigan (Ann Arbor, MI, USA; HUM00201307).
Descrição
Erratum in Correction to Lancet Diabetes & Endocrinology 2026; 14: 105-08. Lancet Diabetes Endocrinol. 2026 Mar;14(3):e6. doi: 10.1016/S2213-8587(25)00426-7. Epub 2026 Jan 12.
Correspondence
Correspondence
Palavras-chave
GLP-1 Receptor Agonists Obesity Obesity Treatment Obesity prevalence Healthcare Access Health Equity Global health Determinantes da saúde e da doença Cuidados de saúde Estados de saúde e da doença INSEF
Contexto Educativo
Citação
Lancet Diabetes Endocrinol. 2026 Feb;14(2):105-108. doi: 10.1016/S2213-8587(25)00356-0
Editora
Elsevier